Counterpart International

Counterpart Bio is a preclinical-stage biotechnology company focused on the intersection of oncology and aging. The company utilizes a proprietary drug discovery platform to identify "counterpart" genes—essential genes that represent vulnerabilities in specific disease contexts, particularly in cancer and senescent cells. By targeting these vulnerabilities through synthetic lethality, Counterpart Bio aims to develop novel small molecule therapeutics for refractory cancers and age-related conditions. The company's approach seeks to eliminate harmful senescent cells and provide more precise, less toxic treatment options for patients with high unmet medical needs.